Dermatology Times

DECEMBER 24, 2024

A panelist discusses how the current treatment options for atopic dermatitis range from topical corticosteroids and calcineurin inhibitors for mild cases to systemic medications such as dupilumab and Janus kinase inhibitors for moderate-to-severe disease, with selection based on factors such as disease severity, patient age, and safety considerations. (..)

Dermatitis 36

Dermatitis Safety Medical Treatments 36

The Dermatology Digest

AUGUST 13, 2024

Drawing upon their 2016 discovery that the interferon response is constantly activated in people with Down syndrome, researchers designed the trial to focus on the autoimmune and inflammatory skin conditions that are common in people with Down syndrome including alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa.

Clinic 74

Clinic Safety Dermatitis Medical 74

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. In addition, due to its unique function on peripheral sensory neurons, EVO756 could provide fast relief of itch associated with inflammatory diseases, such as atopic dermatitis.

Safety 74

Safety Office Dermatitis Clinic 74

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

Dermatology Times

JANUARY 13, 2025

A panelist discusses how health care providers can address patients concerns about topical treatment side effects in atopic dermatitis by providing education about proper application, expected outcomes, and the strong safety profile of modern topical medications.

Dermatitis 36

Dermatitis Safety Education Medical 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab. The National Institute for Health and Care Excellence (NICE) now recommends lebrikizumab (Ebglyss, Almirall S.A.)

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Storrs Medical Dermatology Professor and Director of CLEAR Eczema Center, at the Oregon Health & Science University, in a news release. “If

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

MARCH 10, 2024

More than two-thirds of people with atopic dermatitis (AD) and darker skin tones treated with lebrikizumab showed improvements in skin clearance and itch relief, according to late-breaking results from a Phase 3 study are being presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

SEPTEMBER 25, 2024

Upadacitinib (Rinvoq, AbbVie) performed well in moderate-to-severe atopic dermatitis (AD) patients with head and neck involvement, according to a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. 307) 67.8 (320) 320) 75.9 (323) 323) 4 to 7.2 severe) 10.5 (152) 152) 47.2 (142) 142) 63.2 (136) 304) 22.3 (319)

Dermatitis 36

Dermatitis Dermatology Eczema Safety 36

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. The most frequently reported TEAEs included nasopharyngitis, acne, upper respiratory tract infection, and atopic dermatitis.

Treatments 36

Treatments Dermatitis Pharmaceutical Eczema 36

The Dermatology Digest

DECEMBER 18, 2023

New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Urge consideration for once-daily dosing of topical medications. Suggest against elimination diets for AD.

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36

The Dermatology Digest

MARCH 9, 2024

Upadacitinib (Rinvoq, AbbVie) 15mg or 30mg cools vexing nighttime itch in people with moderate-to-severe atopic dermatitis (AD), according to new research presented at the American Academy of Dermatology’s annual meeting in San Diego.

Dermatitis 36

Dermatitis Safety Medical Dermatology 36

The Dermatology Digest

DECEMBER 14, 2023

Ofir Cohn PhD , Boston Children’s Hospital, Boston, MA Deciphering how genetic variation associated with risk of eczema impacts human dendritic cell subset function Liwen Deng BS, PhD , President & Fellows of Harvard College, Boston, MA S. in subsequent National Institutes of Health (NIH) funding to support further research.

Eczema 36

Eczema Dermatitis Hospital Networking 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Topical or systemic AD medications were not permitted during the study.

Safety 36

Safety Therapy Dermatitis Eczema 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. In addition, due to its unique function on peripheral sensory neurons, EVO756 could provide fast relief of itch associated with inflammatory diseases, such as atopic dermatitis.

Safety 36

Safety Office Dermatitis Clinic 36

The Dermatology Digest

AUGUST 13, 2024

The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis. Nemolizumab was generally well tolerated, and its safety profile was consistent with the phase II trial, and between the OLYMPIA 1 and 2 trials.

Dermatitis 36

Dermatitis Clinic Safety Dermatology 36

The Dermatology Digest

JANUARY 30, 2024

The 2023 PeDRA Research Grant recipients are: Joyce Teng, MD, PhD of Stanford University, will conduct a project titled “ A Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of a Hypertonic Gel in the Treatment of Pediatric Cutaneous Pyogenic Granuloma.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

Aesthetics Advisor

MARCH 10, 2024

Randomized, double-blind, controlled trials suggest that excluding certain foods, such as eggs and chicken, can significantly improve atopic dermatitis. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Previously, I talked about the safety and efficacy of other, more natural treatments.

Eczema 36

Eczema Diet Dermatitis Document 36

The Dermatology Digest

DECEMBER 21, 2023

Janus kinase (JAK) inhibitors are revolutionizing the way certain inflammatory diseases such as atopic dermatitis (AD) are being treated, but a more nuanced approach may be needed in modulating JAK activity for conditions like asthma. This is the main takeaway message from a new study in the December 21, 2023, issue of Cell.

Dermatitis 36

Dermatitis Eczema Safety Dermatology 36

The Dermatology Digest

MARCH 11, 2022

And data from the 40-week, long-term extension study showed an impressive remittive effect and continued safety. Patients underwent washout of existing treatments for psoriasis except for non-medicated emollients and were stratified at enrollment according to baseline PGA. and 0.9%, respectively.” in the two trials.

Safety 36

Safety Dermatology Treatments Dermatitis 36

Art of Dermatology

AUGUST 28, 2023

Alcohol is now proven to shorten our telomeres , the “safety tips” on the ends of our DNA strands that keep them from unraveling and which keep our cells young and behaving properly. This means it’s not recommended for those with liver disease to use the medication. When our telomeres shorten, we age faster.

Rosacea 36

Rosacea Dermatitis Skincare Routine Hydration 36

The Dermatology Digest

DECEMBER 20, 2023

The company is also conducting a 250-patient phase 2b trial of its topical JAK 1/3 inhibitor, called ATI-1777 in atopic dermatitis. Secondary measures of efficacy, as well as safety and pharmacokinetics, will also be assessed. The primary efficacy endpoint is the percent change in EASI over 4 weeks. Billingsley, MD.,

Dermatology 36

Dermatology Surgery Eczema Office 36

US Dermatologt Partners

JANUARY 24, 2024

That starts with a complete medical and health history followed by a discussion of all current and past psoriasis symptoms and the development of a care plan. Thirty years ago, treatments were limited to crude methods such as tar, topical steroids, and medications with significant risks.

Management 36

Management Skin Health Medical Dermatology 36

Aesthetics Advisor

JUNE 16, 2024

Again, this may sound like sci-fi (a tall order for the medical community, let alone labs that make moisturizers), but there are already ways to make your skin not just look younger but act younger too. But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.”

Injections 36

Injections Aromatherapy Ingredients Moisturization 36

Alison Bladh

JANUARY 1, 2025

Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Journal of Cosmetic Dermatology.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

First Derm

DECEMBER 26, 2023

Recent studies indicate that dry, itchy scalp is a significant global issue, with about 40% of the world’s population seeking medical help for symptoms related to scalp dryness. [1] Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a.

Management 49

Management Dermatitis Eczema Consultation 49

First Derm

FEBRUARY 7, 2024

Transmission Cycle : The disease is contracted through skin contact with contaminated freshwater, where parasitic worms from infected snails penetrate human skin, underscoring the importance of water safety. Understanding the early and chronic symptoms of the infection is important for timely medical intervention and management.

Treatments 52

Treatments Sanitation Management Medical 52

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has given its nod to topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis. The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. in seborrheic dermatitis. in seborrheic dermatitis.

Dermatitis 36

Dermatitis Safety Clinic Medical 36

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 42.3% difference vs. placebo. In the lower dose group, 36.3% difference vs. placebo.

Dermatitis 36

Dermatitis Safety Office Eczema 36

The Dermatology Digest

JULY 21, 2023

Pandya, MD, Director, Pigmentary Disorders Clinic, Palo Alto Foundation Medical Group, Sunnyvale, California; and Adjunct Professor of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas “This is the most exciting time of my career when it comes to treatment of vitiligo.

Treatments 36

Treatments Safety Medical Networking 36

The Dermatology Digest

JANUARY 8, 2024

Kimball, MD, MPH, a professor of Dermatology at Harvard Medical School and the President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, in a news release. These data will be presented at a future medical congress. Serious adverse events (SAEs) occurred in 5.3%

Medical 36

Medical Clinic Therapy Eczema 36

The Dermatology Digest

AUGUST 4, 2023

The authors] looked at data from 1993 to 1998 from the National Ambulatory Medical Care Survey, which unfortunately was only 589 records. Many patients are not medical or financial candidates for biologic or oral therapy, said Dr. Richard. It has a great [safety and efficacy] profile. Many patients prefer non-systemic options.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

US Dermatologt Partners

SEPTEMBER 23, 2024

We know that UV radiation and environmental toxins damage the cells in our skin and increase risks for medical conditions such as skin cancer, as well as accelerate the aging process cosmetically. Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes.

Treatments 41

Treatments Chemical Peels Skincare Routine Sun Protection 41

The Dermatology Digest

FEBRUARY 8, 2024

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

FEBRUARY 24, 2025

improved atopic dermatitis (AD) across all primary and secondary efficacy endpoints, with significant improvement as early as Week 1 on multiple efficacy endpoints in kids aged 2 to 5, according to the INTEGUMENT-PED Trial. Roflumilast cream 0.05% (Zoryve, Arcutis Biotherapeutics, Inc.) As previously reported, at Week 4, 25.4% of patients.

Eczema 67

Eczema Dermatitis Safety Dermatology 67

The Dermatology Digest

FEBRUARY 26, 2025

Food and Drug Administration (FDA) accepted Arcutis Supplemental New Drug Application (sNDA) for roflumilast cream 0.05% (Zoryve) for the treatment of children aged 2 to 5 with mild-to-moderate atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) target action date is set for October 13, 2025. At Week 4, 25.4%

Safety 36

Safety Dermatitis Portfolios Clinic 36